Coagulopathy in coronavirus disease 2019 (COVID-19) displays unusually. Not only do patients display impaired fibrinolysis, but also platelet aggregation, inflammation, and microthrombi. Understanding this pathology could help healthcare workers treat these symptoms, often associated with low survival levels in severe COVID-19 patients.
A group of researchers from Columbia University has observed the mechanisms of hypercoagulability in COVID-19, finding a significant increase in fibrin-mediated clot viscosity, but no mechanism behind this observation. To further explore this phenomenon, scientists have investigated the presence of specific biomarkers in hospitalized COVID-19 patients.
